No Evidence of Pharmacokinetic Drug-Drug Interaction in Healthy Subjects Between Coadministered Grazoprevir (MK-5172)/Elbasvir (MK-8742) and Sofosbuvir

William L. Marshall1,2, Wendy W. Yeh3, Crystal Bethel-Brown1, Daria Stypinski1, Patrice Auger4, Christine Brandquist2, Dana Gill2, John Brejda1, Luzelena Caro2, Patricia James1, Xiaobi Huang5, Zifang Guo1, Monika Martinho1, H-P Feng1, Danielle Armas6, Mariam Iwamoto7, Joan R. Butterton
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Celerion, Tempe, AZ, USA

Abstract

Background and aims: Grazoprevir (GZR, MK-5172), a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease, and elbasvir (EBR, MK-8742), an inhibitor of the HCV NS5A repli-complex, are being developed as a once-daily (QD) fixed-dose combination therapy for the treatment of chronic HCV infection. This study evaluated the effect of coadministration of sofosbuvir (SOF) with GZR/EBR (mixed-administration group) on the pharmacokinetics of SOF compared to single-dose administration of SOF alone, when coadministered with GZR/EBR, in healthy subjects.

Methods: Coadministered Grazoprevir (MK-5172)/Elbasvir (MK-8742) and Sofosbuvir

Results and Discussion

Table 2. Statistical comparisons of plasma pharmacokinetics of GS-331007 following the administration of a single dose of 400 mg sofosbuvir with or without the coadministration of multiple doses of 200 mg grazoprevir + 50 mg elbasvir QD in healthy adult subjects

<table>
<thead>
<tr>
<th>Parameter</th>
<th>GS-331007 Alone</th>
<th>Grazoprevir + Elbasvir</th>
<th>SOF + Grazoprevir + Elbasvir</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Cmax† (ng/mL)</td>
<td>16 1440 (1270, 1630)</td>
<td>16 1250 (1100, 1410)</td>
<td>0.87 (0.78, 0.96)</td>
<td>16.209</td>
</tr>
<tr>
<td>C24‡ (ng/mL)</td>
<td>16 86.9 (74.7, 101)</td>
<td>16 133 (117, 150)</td>
<td>1.53 (1.43, 1.63)</td>
<td>10.976</td>
</tr>
<tr>
<td>Tmax§ (hr)</td>
<td>16 3.01 (1.51, 5.01)</td>
<td>16 3.00 (1.99, 5.00)</td>
<td>1.00 (0.99, 1.00)</td>
<td>2.898</td>
</tr>
</tbody>
</table>

Subject Demographics

Table 3. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Statistical comparisons of plasma pharmacokinetics of SOF following the administration of a single dose of 400 mg sofosbuvir with or without the coadministration of multiple doses of 200 mg grazoprevir + 50 mg elbasvir QD in healthy adult subjects

<table>
<thead>
<tr>
<th>Parameter</th>
<th>GS-331007 Alone</th>
<th>Grazoprevir + Elbasvir</th>
<th>SOF + Grazoprevir + Elbasvir</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Cmax‡ (ng/mL)</td>
<td>16 1440 (1270, 1630)</td>
<td>16 1250 (1100, 1410)</td>
<td>0.87 (0.78, 0.96)</td>
<td>16.209</td>
</tr>
<tr>
<td>C24‡ (ng/mL)</td>
<td>16 86.9 (74.7, 101)</td>
<td>16 133 (117, 150)</td>
<td>1.53 (1.43, 1.63)</td>
<td>10.976</td>
</tr>
<tr>
<td>Tmax§ (hr)</td>
<td>16 3.01 (1.51, 5.01)</td>
<td>16 3.00 (1.99, 5.00)</td>
<td>1.00 (0.99, 1.00)</td>
<td>2.898</td>
</tr>
</tbody>
</table>

Subject Demographics

Table 3. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures

Table 1. Summary of subject disposition and characteristics can be found in Table 3

Safety and Tolerability

Conclusions/Discussion

References

Disclosures